Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines

Vertex Pharmaceuticals (Europe) Limited announced it has entered into an innovative access contract with the Danish pharmaceutical and procurement organization, Amgros. Effective from today, this first-of-its-kind contract includes current and future CFTR modulator medicines, and means eligible Danish cystic fibrosis (CF) patients will have access to all current medicines as well as future medicines after regulatory approval.

“We’re delighted to have collaborated with Amgros to finalize this pioneering contract,” said Ludovic Fenaux, Senior Vice President, International Commercial Operations at Vertex. “Our medicines have fundamentally changed the way CF is treated and we share the community’s sense of urgency for rapid access. This contract also allows Danes with CF to be among the first in the world to access our future CFTR modulator medicines.”

“I would like to thank Vertex for its will and engagement to make this deal. Most of all, I’m happy that we have made it possible to offer a group of patients the newest treatments. And naturally, I’m also enthusiastic that this new kind of contract gives the Danish hospitals and their owners in the regions much more predictable budgets – at times of rising costs of hospital medicines,” said Flemming Sonne, CEO at Amgros.

Earlier this month, an agreement in Austria was also secured to provide access to ORKAMBI (lumacaftor/ivacaftor) for all children with CF ages 6 through 11 with two copies of the F508del mutation. This agreement is also effective from today.

Austrians and Danes with CF join patients in other countries around the world who have access to CFTR modulator treatments, including Australia, Germany, Ireland, Italy, the Netherlands, Sweden and the U.S.